VREOF
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when Vireo Growth Inc. publishes a filing, an earnings call transcript or a press release.
Get VREOF alertsTyson Macdonald is recorded as CFO at Vireo Growth Inc. (VREOF). The newest filing on record that lists Tyson Macdonald as CFO at Vireo Growth Inc. (VREOF) is dated April 16, 2026. Vireo Growth Inc. reported in an 8-K filed December 23, 2024 that Tyson Macdonald was appointed CFO. Vireo Growth Inc. reported in an 8-K filed December 23, 2024 that Tyson Macdonald was appointed Chief Financial Officer, effective December 17, 2024. The proxy statement of Vireo Growth Inc. reports total compensation of $10,269,840 for Tyson Macdonald in fiscal 2025, including a base salary of $500,000. Disclosed compensation is on record for 3 fiscal years. Tyson Macdonald has spoken on 6 earnings calls across 1 company, most recently for Vireo Growth Inc. on August 11, 2026. Vireo Growth Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Vireo Growth Inc. includes Amber H. Shimpa (CEO), Amber Shimpa (CEO), John Mazarakis (CEO, Chairman and Board Member) and 7 others.
“Tyson Macdonald, former partner at TrueRise Capital, has been appointed to the role of CFO, effective immediately.”
“On December 17, 2024, the Board appointed Tyson Macdonald, age 50, as Chief Financial Officer of the Company.”
“I'll run through a quick summary of key income statement line items and then review our balance sheet in more detail. Second quarter gap revenue of $209.3 million increased 335% year-over-year on a reported basis.”
“I'll run through a quick summary of key income statement line items in the reviewer balance sheet in more detail.”
“I'll run through a quick summary of key income statement line items and the reviewer balance sheet in more detail.”
“I'll run through a quick summary of key income statement line items and then review our balance sheet in more detail. Second quarter gap revenue of $48.1 million increased 91.4% year-over-year driven by the partial quarters of contributions from the three merger transactions that we closed during the second quarter.”
Start not stated–present
Last confirmed April 16, 2026
VREOF
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Vireo Growth Inc. (VREOF) | Chief Financial Officer | $500,000 | $10,269,840 |
| 2024 | Vireo Growth Inc. (VREOF) | Chief Financial Officer | $15,385 | $815,385 |
| 2023 | Vireo Growth Inc. (VREOF) | Chief Financial Officer | — | — |